Belantamab mafodotin

GlaxoSmithKline (GSK) Pharmaceuticals has announced its financial results for the first quarter ended June 30, 2026. During the quarter, the company delivered strong growth across both its core and innovative portfolios. The performance reflects continued progress in the company's portfolio transformation strategy, supplemented by execution excellence, and a favorable base effect from the comparable period last year. Revenue for the quarter stood at INR 924 crore, up 15 percent Year-on-Year (YoY). Profit After Tax (PAT) increased by 24 percent to INR 253 crore, while EBITDA margins stood at 32 percent. The General Medicines portfolio grew strongly during the quarter, with the top 5 promoted brands outperforming the market (EI* >100; Source: IQVIA). Key promoted brands such as Augmentin, Ceftum and T-Bact reinforced their leadership positions in their respective categories, driven by a combination of deeper scientific and in-clinic engagement, omnichannel execution, and pricing measures. The Respiratory portfolio continued to further the management of chronic respiratory diseases with Nucala (mepolizumab) benefitting a large number of patients and Trelegy Ellipta gaining traction through new access pathways. The vaccines business grew through continued leadership in the self-pay private pediatric vaccines market, led by Infanrix Hexa and Fluarix Tetra. In the adult vaccination space, the company’s focus on elderly patient-cohorts with underlying Cardiovascular and Metabolic Diseases (CVMD) led to stronger endorsement from the healthcare professional community, translating to higher vaccinations with Shingrix (Recombinant Herpes Zoster Vaccine, Adjuvanted). The oncology business, led by specialised therapies Jemperli (dostarlimab) and Zejula (niraparib), has grown significantly since its launch in August last year. Jemperli is now the leading immunotherapy for first line primary advanced and recurrent endometrial cancer while Zejula is among the top PARP inhibitors in the maintenance treatment of recurrent ovarian cancer. Together, both therapies have touched the lives of a growing number of women suffering from gynecological malignancies, with GSK committed to expanding access and patient reach. Commenting on the results, Bhushan Akshikar, Managing Director (MD), GSK India, said, "GSK India's broad-based growth demonstrates the resilience of the core General Medicines and Vaccines portfolio and the growing contribution of the innovative business. This growth was enabled by a relentless focus on scientific excellence, sharper execution in the field and meaningful investments in technology and talent development. With a strong innovation pipeline and launch opportunities ahead, we are well-positioned to deliver sustainable growth and meaningful impact for millions of patients in India." The company has made progress in strengthening supply chain resilience through diversified sourcing, enhanced contingency planning and improved end-to-end visibility, substantially mitigating disruptions experienced in recent quarters. Looking ahead, GSK India is preparing for key pipeline launches. Blenrep (belantamab mafodotin), an anti-BCMA ADC therapy indicated for second-line treatment in relapsed or refractory multiple myeloma in adults, is set for launch. Arexvy, a vaccine to prevent Lower Respiratory Tract Disease (LRTD) caused by Respiratory Syncytial Virus (RSV) in adults over 60 years of age and older adults (50 to 59 years) at high-risk, has received Marketing Authorisation (MA).

With quarterly earnings underway, BioPharma Dive is providing a snapshot of some companies results and how theyre being received by investors. Today, were offering insight into the latest numbers from Biogen, AstraZeneca and GSK.Biogens resilient quarterBiogen, with its latest earnings report out Wednesday, drummed up more confidence in its product portfolio on Wall Street.The Boston-area biotechnology company reported $2.7 billion in revenue between April and the end of June, a 3% increase from the same period a year prior. Diluted earnings per share were 66 cents under generally accepted accounting principles and $3.60 when adjusted. In a note to clients, Jefferies analyst Andrew Tsai wrote that analysts, on average, expected revenue to come in at $2.5 billion and non-GAAP EPS at $2.88.Several of Biogens flagship products contributed to the beat. Sales of Spinraza, a treatment for an uncommon muscular disorder, were up 7% from the first quarter, to $402 million. The $381 million Biogen got from royalties tied to Roches multiple sclerosis drug Ocrevus were about $21 million above analyst forecasts. And Biogens broader MS franchise, though pressured by competition from copycat drugs, still delivered $963 million on the quarter. The business continues to be more resilient than expectations, wrote RBC Capital Markets analyst Brian Abrahams.Newer additions to the portfolio impressed as well. Sales of Skyclarys, a rare disease medicine Biogen picked up through its $7.3 billion purchase of Reata Pharmaceuticals, rose to $168 million, topping consensus estimates of $157 million. Biogen also recorded $30 million and $97 million, respectively, from two drugs from the recent acquisition of Apellis Pharmaceuticals. Both of those figures exceeded analyst predictions, according to Tsai, who added that the earnings in full showcase resiliency in Biogens base business.Leqembi, the closely watched medicine for Alzheimers disease that Biogen co-developed with Japans Eisai, grew 15% year-over-year to $184 million in global sales.The Food and Drug Administration recently started allowing patients to begin treatment with Leqembi at home, using a form of the medicine given as an under-the-skin shot. The latest Leqembi figures could help instill confidence that this new launch will be coming off of a solid base and could catalyze a pickup in sales in the near to medium term, helping to reclaim market share, Abrahams wrote.In its report, Biogen updated its full-year guidance. It now expects revenue to increase by a mid-single-digit percentage, and non-GAAP EPS to settle somewhere between $12 and $13. Thats down from the previous range of $15.85 to $16.85, in good part because of dilution and research costs from the Apellis deal.Biogen shares were up almost 5%, to trade just over $215 apiece, by late Wednesday morning. Jacob BellAstraZenecas growth pitchUp until recently, AstraZeneca had been on the kind of extended tear that separated it from many large pharmaceutical peers. A series of successes in cancer and other areas of drug research has helped the company more than double its yearly earnings between 2015 and 2025. Executives think the company can reacheven higher and hit $80 billion in sales by 2030, nearly $21 billion more than AstraZeneca pulled in last year.We have the science, we have the pipeline, and we have the team to make that happen, CEO Pascal Soriot assured analysts and investors on a Monday conference call.Wall Street has reason to be nervous, though. Etcamah, a breast cancer drug important to AstraZenecas future, has been delayed in the U.S. The company also suffered a major setback earlier this month when eplontersen, a drug its been counting on, fell short in a big study in a deadly heart condition. That trial was widely expected to succeed and executives were accordingly optimistic. Its failure was therefore seen as a credibility loss given managements confidence level, one analyst wrote at the time. Company shares have fallen more than 10% since.Still, executives are confident AstraZeneca will hit its target. The $80 billion figure is risk-adjusted, Soriot said, adding that AstraZeneca would far surpass that total if “everything worked. Etcamah, the cancer drug Datroway and newly approved blood pressure medication Baxfendy could all peak at more than $5 billion in annual sales.AstraZeneca now believes a respiratory disease drug currently known as tozorakimab could hit that mark, too, following positive results that surprised analysts earlier this year. Its earnings presentation listed a smattering of weight loss and oncology programs as having $5 billion-plus sales potential, too. All should produce pivotal results before 2030.To Soriot, those coming readouts suggest the company doesnt need to do more deals to meet its mark. There may be other setbacks, but AstraZeneca is planning as if its success rate in Phase 3 will be at or below the industry average, even though the companys performance has consistently been higher, he said.The likelihood that there will be puts and takes is part of how we plan, Soriot added. We've taken this into account. Ben FidlerGSKs oncology pushBest known for its HIV drugs, respiratory disease medicines and vaccines, GSK has for years worked to build an oncology business, too. That effort is now the centerpiece of an accelerate growth plan, through which GSK aims to reach 40 billion in annual revenues by 2031 even as key patents fortifying its HIV products expire.Dealmaking has helped the British pharma acquire cancer drugs like Jemperli, Zejula and Blenrep. But that business only brought in 600 million in the second quarter and 2 billion in 2025, a small fraction of GSKs overall revenue and much lower than what the sectors major oncology players report.In an earnings presentation Tuesday, though, the company spotlighted its next wave of oncology drugs as critical revenue drivers in the years ahead. Its confidence is derived from their differentiation and potential benefit to patients, Chief Scientific Officer Tony Wood told analysts on a conference call.Chief among those prospects are two antibody-drug conjugates licensed from China-based biotech Hansoh Pharmaceutical. Known as riz-rez and mo-rez, respectively, both have rapidly advanced through clinical development, and riz-rez has now succeeded in two Phase 3 trials in China. Global studies for both are underway.GSK also has high hopes for a pair of lung cancer drugs it acquired through a nearly $11 billion acquisition of Nuvalent in June. One, named Jideytro, won approval from U.S. regulators earlier this month. Another, dubbed neladalkib, is currently under regulatory review, with a decision expected this November. Both are also in testing in first-line lung cancer, and have already shown best-in-class efficacy profiles, Hesham Abdullah, GSKs global head of oncology R&D, said on Tuesdays call.GSK claimed to have the capacity for additional dealmaking, too, with CSO Wood noting that the company wants to boost its mid-stage drug pipeline with medicines that address efficacy or tolerability gaps.But the key message to investors was that GSK increasingly views oncology as a major future growth pillar, supported by a rapidly expanding pipeline rather than reliance on a small number of products, wrote Jefferies analyst Michael Leuchten, in a client note. Delilah Alvarado '